CAMBRIDGE, England and CAMBRIDGE, Massachusetts, September 10 /PRNewswire-FirstCall/ -- Acambis plc (“Acambis”) will announce its Results for the second quarter ended 30 June 2004 on Tuesday, 21 September 2004.
The results announcement will be released at 7.00 am BST. A conference call for analysts will be held at 11.00 am BST. For details, contact Mo Noonan at Financial Dynamics on telephone number +44-207-269-7116. An instant replay of the call will be available until 21 October 2004 on telephone number UK: +44-207-365-8427 and US: + 1-617-801-6888. The pin code is 70777206.
An audio webcast of the call will also be available via Acambis’ website at http://www.acambis.com/. The webcast replay will be available until Wednesday, 21 September 2005.
About Acambis
Acambis is a leading developer of vaccines to prevent and treat infectious diseases. Acambis is developing an investigational second-generation smallpox vaccine and, under a unique arrangement given the threat of smallpox being used as a bioterrorist weapon, is manufacturing emergency-use stockpiles of this investigational vaccine for the US Government and other governments around the world. Acambis is establishing a travel vaccines franchise through its US-based subsidiary Berna Products Corporation, which markets Vivotif(R), the world’s only licensed oral typhoid vaccine, in North America. Acambis has a number of other potential travel vaccines in development and is also developing an investigational vaccine against the West Nile virus, which has spread to 46 US States in the last four years.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary listing is on the London Stock Exchange (ACM) and its shares are listed in the form of American Depositary Receipts on NASDAQ (ACAM). More information is available at http://www.acambis.com/.
Acambis plc
CONTACT: Acambis plc, Lyndsay Wright, Director of Communications, Tel:+44-1223-275-300. Financial Dynamics, Mo Noonan, Tel:+44-207-269-7116
